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Background: Breast milk provides nutrition for infants but also delivers other bioactive
factors that have key protective and developmental benefits. In particular, cytokines are
thought to play a role in immunomodulation, although little is known about their impact
on health outcomes in early life.
Objective: The purpose of this pilot study was to evaluate the relationship between
cytokines in breast milk and infant growth outcomes in a low-income setting.
Methods: 100 mother-infant pairs were followed up to 2–3 months postpartum as
part of a prospective longitudinal cohort study in urban Gambia, West Africa. The
concentrations of 9 pro-inflammatory cytokines (IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13,
IFN-γ, TNFα), IGF-1 and TGFβ2 were measured in colostrum within 12 h of birth and in
breast milk at the final visit, scheduled between day 60 and 89 postpartum. Infant weight
was recorded and converted to weight-for-age Z-scores (WAZ) at the same time points.
Growth outcomes were defined in our study as (a) change in WAZ between birth and final
visit (b) WAZ at final visit. Linear regression analysis was used to determine the ability of
colostrum and breast milk cytokine concentrations to predict growth outcomes up to
2–3 months postpartum.
Results: Gambian infants demonstrated growth faltering across the first 2–3 months
postpartum. There was no significant relationship between cytokines in colostrum and
subsequent change in WAZ between birth and the final visit, in either unadjusted or
adjusted models. However, cytokines in mature breast milk, TNFα, IFNγ, IL1β, IL2, IL4,
and IL6, were weak negative predictors of WAZ scores at the final visit, in unadjusted
models (p < 0.05). When adjusted for maternal anemia (as a proxy for maternal nutrition),
TNFα and IL6 remained significant predictors (p < 0.05).
Conclusions: Variations in breast milk cytokine levels do not play a substantial role in
the growth faltering observed across early infancy. The potential contribution of other
factors, such as micronutrients, hormones or human milk oligosaccharides, must be
elucidated. Cytokine levels in mature breast milk were weakly predictive of poor infant
growth, possibly reflecting a “read-out” of suboptimal maternal health and nutrition.
Keywords: breast milk, colostrum, cytokine, growth, weight, infant, neonate, immunity
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INTRODUCTION
Human breast milk (BM) provides nourishment for infants but
also delivers a range of non-nutritive bioactive factors that have
key protective and developmental benefits, including actively
shaping and priming the infant immune system (1–6). It is
increasingly recognized that the complex effects of colostrum and
BM on the diverse nature and function of the infant microbiome
are key to coordinating these roles (7–10). Moreover, biologically
active substances influence the infant’s response to energy intake
and metabolism (3, 11–13). BM composition, however, is very
diverse, dynamic, varying between women and over the course
of lactation, and sensitive to both maternal and environmental
factors (14–16). The exact nature of these variations, their impact
on infant morbidity and growth outcomes and the exploitative
potential for future interventions has yet to be fully elucidated
(10, 17–22).
Cytokines and growth factors have been identified as
important bioactive components within BM and are found
in differing concentrations (23, 24). It is hypothesized
that the mammary gland is the principal source of these
compounds in milk (6, 25). In addition, leukocytes isolated
from expressed human milk have demonstrated the ability
to secrete a small number of cytokines (26). Once ingested,
milk-derived cytokines and growth factors pass through the
infant’s gastrointestinal tract, resisting proteolysis and retaining
their bioactivity. They subsequently interact with specific gut
epithelial receptors, enabling them to be absorbed from the
gastrointestinal tract and thereby enter the infant circulation
(12, 18, 19, 27).
Cytokines, particularly in colostrum, are thought to play
a key role in immunomodulation, including promoting sIgA
production, mediating infant immune responses, for example
through B cell growth and differentiation, and boosting
development of intestinal tolerance (4, 5, 12, 28, 29). However,
the impact of these immune factors on early infant growth and
body composition is less well-documented.
Growth faltering in sub-Saharan Africa, including The
Gambia, has been well-established previously (30) and poor
growth in infancy and early childhood has adverse consequences
for child mortality, and on subsequent adult stature and health
outcomes (31, 32). At the same time, the rate of breast
feeding is high in these low-income populations and is the
only sustainable feeding option for many. Despite intensive
efforts aimed at achieving optimal nourishment for mother and
child, substantial infant growth faltering remains, suggesting the
potential importance of other non-nutritive factors (30, 33).
A more thorough understanding of how natural variation in
BM bioactive components influences infant development and
may exacerbate or protect against growth failure would help
guide the development of preventative and therapeutic strategies,
particularly in low-income settings (21, 31).
Abbreviations: IL, Interleukin; IGF, Insulin-like growth factor; EGF, Epidermal
growth factor; TGF, Transforming growth factor; HMO, Human milk
oligosaccharide; Hb, Hemoglobin; BM, Breast milk; WAZ, Weight-for-age Z
score; SD, Standard deviation; CI, Confidence interval.
The aim of this study was to evaluate the relationship between
the cytokine and growth factor profile in human BM and infant
growth outcomes in the first 3 months post-partum in The
Gambia, a low-income country in West Africa.
MATERIALS AND METHODS
Study Setting, Population, and Ethics
Samples for this project were made available as part of a larger
prospective longitudinal cohort study on Group B Streptococcus
infection, conducted between 1st January and 31st December
2014, in an urban area of The Gambia, West Africa (34). The
Gambia is a low-income country with an estimated 79,000 births
annually and an infant mortality rate of 42/1,000 (2016) (35).
Moreover, 47% of infants are exclusively breastfed under 6
months and 98% breastfed (mixed and exclusive) beyond the
first year of life (2013) (35). The cohort in this sub-project
consisted of 100 consecutive pregnant women and their infants
followed up across the first 2–3 months postpartum in two
government health centers offering antenatal care to women.
These centers were considered representative samples of the
standard of care available to Gambian women in urban settings,
with a combined birth rate of ∼12,500 births annually(34).
Women between the ages of 18–40 years who had a negative
HIV test and low-risk, singleton pregnancy (no evidence of
pre-eclampsia, cardiomyopathy, maternal gestational diabetes,
placenta praevia, twin pregnancy) were recruited in the final
trimester of pregnancy after giving informed consent. They
were excluded if they did not plan to breastfeed or remain
in the nearby area for the first 3 months postpartum. Infant
exclusion criteria included marked prematurity (<32 weeks
gestation), low birth weight (<2.5 kg), congenital abnormalities
or requiring resuscitation at the time of delivery with subsequent
transfer to a neonatal unit. Further demographic and recruitment
details, including eligibility, inclusion and exclusion criteria
and consent protocol, are summarized in Figure 1 and have
previously been published (34). The study was approved by the
joint Gambian Government/Medical Research Council Research
Ethics Committee, SCC 1350 V4.
Data Collection
Following birth, participants were monitored daily at home until
day 6 and then asked to return to the clinic for a final visit
which was scheduled between day 60 and 89 postpartum. Details
were documented via standardized questionnaires and included
maternal factors (age, ethnic origin, gravida, parity, weight, blood
pressure, hemoglobin concentration, illnesses in pregnancy, use
of antibiotics/medications/ traditional medicines/antimalarial
prophylaxis) and infant factors (anthropometry, sex, morbidity,
vaccinations, vital signs, feeding). Full details on data collection
have been described previously (34). Anthropometric measures
were performed by trained field nurses at birth and at the final
visit; infant weight was measured using electronic baby scales
(model 336; Seca, UK), to the nearest 0.01 kg. Weight-for-age
Z score (WAZ) was calculated based on the WHO growth
standards (36).
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 1 
Antenatal visits 
(n=14428)
Hospital deliveries 
(n=6024)
Excluded due to maternal 
complications (n=353):
- Obstructed labour = 22
- Antepartum or postpartum 
hemorrhage = 66
- Pre-eclampsia = 213
- Eclampsia = 52
- Maternal deaths = 77
Healthy pregnant 
women (n=5671)
Excluded due to neonatal 
complications (n=2010):
- Birth weight < 2.5kg = 1090
- Prematurity = 773
- Stillbirths = 106
- Neonatal deaths = 41
Eligible mother-infant
pairs (n=3661)
Mother-infant pairs 
recruited to primary 
study at birth (n=750)
Consecutive mother-
infant pairs included in 
sub-study at birth 
(n=100) 
Attended final visit 
scheduled at day 60-89
postpartum (n=94)
Loss to follow up (n=6) 
- Infant death = 1
- Withdrawal from study 
= 5
Out-of-hospital 
deliveries (n=8404)
FIGURE 1 | Flow diagram to demonstrate recruitment, retention and loss to follow up (34).
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Colostrum and Breast Milk Sample
Collection
Colostrum was collected within 12 h of birth and mature BM was
collected at the final visit. After washing their hands with soap,
mothers wiped each breast with a 0.02% chlorhexidine wipe and
then hand-expressed their milk prior to feeding their infant; the
first 0.5 mls was discarded and then 2–3mL of colostrum and 4–
5mL of BM was collected from both breasts into sterile plastic
containers. Milk samples were immediately stored on cold packs
at 4◦C and transported to the laboratory within 6 h of collection
(37, 38).
Laboratory Procedures
BM samples were centrifuged at 3,200 rpm for 30min to separate
whey and lipid layers. The lipid layer was removed with a scalpel
and stored separately. The whey layer was stored in 1mL aliquots
and frozen at −70◦C. It was transferred to 5mm NMR capillary
tubes for analysis (37, 38).
Cytokine Quantification
Assays were run in duplicate and concentrations of IL-1β, IL-2,
IL-4, IL-6, IL-10, IL-12, IL-13, IFN-γ, TNFα, IGF-1, and TGFβ2
in colostrum and BM were determined by electroluminescence
using kits from Meso-Scale Discovery Multi-Spot Kit (MSD,
Rockville, MD, United States). Laboratory experiments were
run according to manufacturer’s protocol, using an eight-point
standard curve. Samples below the lower limit of detection
were allocated a concentration for each cytokine of half the
lower limit of detection to aid the statistical analysis and as
per manufacturer’s instructions (Supplementary Table 1). The
coefficient of variance (CoV) for the assay was 25% (37, 38).
Growth Outcomes
Growth outcomes were defined in our study as (a) change in
WAZ between birth and final visit b) WAZ at final visit. Children
with Z scores below −2 were defined as underweight (WAZ ≤
−2) (36).
Statistical Analysis
The sample size was based on a sample of convenience for a pilot
study of 100 mother-infant pairs as there are no published studies
of expected cytokine values in milk and their association with
growth outcomes on which to base our calculations. Descriptive
statistics were calculated for maternal and infant demographics,
infant growth parameters and cytokines in colostrum and
mature BM. Shapiro-Wilk test was used to assess the normality
of the distribution of cytokines. Because all measurements
deviated significantly from normality, non-parametric tests were
used in further analysis. Potential differences and associations
between cytokines in colostrum and mature BM were calculated
using Wilcoxon rank-sum and Spearman rank correlation
tests, respectively. Differences in WAZ scores between male
and female infants were calculated using Wilcoxon rank sum
tests. All other univariate analysis was performed using simple
linear regression on log transformed data. Multivariate linear
regression (including stepwise regression) analysis was then used
to determine the ability of cytokine concentrations to predict
longitudinal growth outcomes in the first 2–3 months post-
partum by analyzing the association between (i) colostrum
cytokines and change in WAZ between birth and final visit
(ii) BM cytokines and WAZ at final visit. Potential maternal
and infant confounders found to be significant in variable
univariate analysis with a p < 0.1 or known to be associated
with infant growth (a priori) were included in the multivariate
models. Maternal hemoglobin (Hb) was categorized as either
Hb <11 g/dL (anemia) or Hb ≥11 g/dL (39). Maternal illness
was categorized as either having none or ≥ 1 self-reported
acutely unwell episodes recorded during pregnancy, regardless of
severity or outcome. Maternal gravida was categorized as either
nil or ≥1 previous pregnancies, regardless of outcome. Maternal
parity was defined as either nil or ≥1 previous pregnancies
carried to a viable gestational age.
All statistical analyses were completed using the statistical
packages STATA version 12 (StataCorp 2013, California CA,
United States), GraphPad Prism version 6.0 (GraphPad Softward
Inc., La Jolla, CA, United States) and R package version 3.4.1.
Differences were considered statistically significant at p < 0.05.
RESULTS
Maternal and Infant Characteristics
A total of 100 mother-infant pairs were included in the analysis.
The mean ± 1 SD maternal age was 25.6 ± 5.7 years and
mean ± 1 SD maternal weight at delivery was 63.4 ± 9.8 kg.
The infants were born at mean gestational age of 39 weeks and
followed up to a mean ± 1 SD of 61.6 ± 1.3 days postpartum;
although scheduling allowed for final visits to occur up to
90 days postpartum, all final visits in this cohort took place
between 60 and 66 days postpartum. All infants were exclusively
breast fed throughout the duration of the study. Demographic
characteristics of mother-infant pairs are summarized in Table 1.
Infants were born with a mean weight ± 1 SD of 3.36 ±
0.48 kg and WAZ ± 1 SD of 0.10 ± 0.99 (Table 2A). However,
substantial growth faltering was seen across the first 2–3 months
postpartum, equivalent to crossing over one major centile band
(Figure 2). Of the 94/100 infants remaining in the study at the
final visit, infants’ WAZ had declined to a mean± 1 SD of−0.59
± 1.20; 71% of infants demonstrated a decline in their WAZ and
15% were underweight by 2–3 months postpartum (WAZ<-2)
(Tables 2A,B). The difference between male and female infant
WAZ scores was non-significant at birth (p = 0.505) and final
visit (p = 0.791). Similarly, the odds ratio of being underweight
and having a decline in WAZ by 2–3 months postpartum did not
differ significantly between the sexes: for male infants, the odds
ratio was 1.4 (CI 0.45–4.41, p = 0.56) and 1.69 (CI 0.68–4.1775,
p = 0.25), respectively.
Cytokines in Colostrum and Breast Milk
83 samples of colostrum (from 100 women) and 90 samples
of mature breast milk (from 94 women) were successfully
collected. In the remaining cases, insufficient sample was
available, either because the mother was unable to express
milk, or due to insufficient sample remaining after the primary
analysis was complete. Colostrum at birth contained significantly
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TABLE 1 | Description of study population.
Variable Value
Maternal age, years (mean ± SD) 25.6 ± 5.7
Maternal weight, kg (mean ± SD) 63.4 ± 9.8
Gestational age at birth, weeks (mean ± SD) 39.0 ± 2.5
Length of post-partum follow-up, days (mean ± SD) 61.6 ± 1.3
MATERNAL Hb CATEGORIES, n (%)
Hb ≥ 11g/dL 33 (40)
Hb < 11g/dL 49 (60)
MATERNAL ILLNESS CATEGORIES, n (%)
Illness during pregnancy 16 (18)
No illness during pregnancy 73 (82)
PARITY CATEGORIES, n (%)
Primiparous 21 (21)
Multiparous 79 (79)
GESTATIONAL AGE CATEGORIES, n (%)
≥37 weeks 76 (76)
< 37 weeks 24 (24)
INFANT SEX, n (%)
Male 50 (50)
Female 50 (50)
Values are rounded to 1 decimal place.
Missing values: maternal weight =12, maternal Hb = 18, maternal illness = 11.
SD, standard deviation; Hb, hemoglobin.
higher concentrations of nearly all cytokines than BM (p <
0.001) (Supplementary Table 2). Furthermore, the percentage of
samples with detectable concentrations was significantly greater
for the majority of cytokines in colostrum when compared to
BM (p < 0.05), with the exception of TNFα, IGF1, TGFβ2, and
IL6 (the latter was almost significant, p = 0.06). Of note, the
levels of IGF1 in colostrum and BM were below the assay limit
of detection in >75% of subjects and, therefore, this data has
been removed from further analysis (Supplementary Table 2).
There were minimal significant associations between the levels
of cytokines in colostrum and in mature milk, with only a weak
positive correlation found with IL12 (r = 0.257, p = 0.023)
(Supplementary Table 3).
Associations Between Maternal/Infant
Factors and Infant Growth Outcomes
Only maternal illness and infant gestational age at delivery were
found to be significant or near significant predictors of change
in WAZ between birth and final visit, in univariate analysis (p
< 0.05) (Table 3). There were no significant maternal or infant
predictors of WAZ at final visit.
Associations Between Cytokines and
Infant Growth Outcomes
The association between colostrum cytokines and change in
WAZ between birth and final visit was non-significant in both
the unadjusted and adjusted models in this Gambian cohort.
Moreover, unadjusted models demonstrated that lower TNFα,
IFN-γ, IL1β, IL2, IL4, and IL6 levels in BM were weakly
associated with a higher WAZ at final visit (p < 0.05).
TABLE 2 | Summary of infant growth data at birth and final visit.
(A) INFANT WEIGHT AND WAZ SCORES .
Infant growth indicator, mean ± SD Birth Final visit
Weight (kg)
Male 3.45 ± 0.43 5.24 ± 0.68
Female 3.27 ± 0.42 4.84 ± 0.74
All 3.36 ± 0.48 5.04 ± 0.74
WAZ score
Male 0.18 ± 0.85 −0.57 ± 1.05
Female 0.02 ± 1.12 −0.61 ± 1.34
All 0.10 ± 0.99 −0.59 ± 1.20
(B) INFANT WAZ CATEGORIES
WAZ categories, n (%) Birth Final visit
≤ −3
Boys 0 0 (0)
Girls 0 3 (100)
All 0 3
−3 <WAZ ≤ −2
Boys 0 8 (72)
Girls 0 3 (27)
All 0 11
> −2
Boys 49 (51) 39 (49)
Girls 48 (49) 41 (51)
All 97 80
All values are rounded to 2 decimal places; WAZ, Weight-for-age Z score; SD, standard
deviation.
Although significant, the β -coefficients were small. When
these models were adjusted for maternal anemia, only TNFα
and IL6 remained significant predictors of WAZ at final visit
(p < 0.05) (Table 4). Other multivariate models were non-
significant.
DISCUSSION
Inmany sub-Saharan African countries, infants are small at birth,
show catch-up growth initially, but then rapidly demonstrate
reduced growth velocity, leading to substantial growth faltering
that becomes maximal by their second year of life (30, 33). Our
findings show a similar pattern with clear growth faltering across
the first 2–3 months postpartum. Identifying the factors that
contribute to this pattern of growth—despite optimal feeding
practices—is important, as developing interventions to optimize
BM bioactive components could reduce the risk of poor growth
and morbidity in early infancy, particularly in low-income
settings (10, 13, 30, 31, 40). Using data from a cohort of mother
infant pairs from urban Gambia, we have shown that variations
in BM cytokine levels do not play a substantial role in the growth
faltering observed across early infancy.
To date, there has been a paucity of studies in the literature
reporting on cytokines and growth factors in BM and their role in
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FIGURE 2 | Mean WAZ scores across the first 2–3 months postpartum.
TABLE 3 | Relationship between maternal/infant factors and difference in WAZ at
birth and final visit.
Maternal/infant factor β p-value
Maternal illness 0.646 0.064
Gestation 0.095 0.077
Maternal age 0.018 0.423
Maternal weight 0.003 0.840
Maternal Hb −0.200 0.449
Gravida 0.082 0.276
Parity 0.085 0.273
Infant sex −0.388 0.140
All values are rounded to 3 decimal places.
Linear regression β coefficients for maternal/infant factors predicting difference in WAZ at
birth and final visit.
WAZ, Weight-for-age Z score; Hb, hemoglobin.
growth and development in the early postnatal period. Previous
studies have primarily focussed on weight gain, exploring
the relationship between BM factors, particularly hormones,
and infant adiposity and risk of obesity (13, 41–47). To
our knowledge, we are the first to examine the relationship
between BM cytokine profile and longitudinal growth outcomes,
specifically WAZ, in the context of early growth faltering in a
low-income setting.
The protective effects of bioactive factors in BM on infant
health and developmental outcomes are thought to be mediated
by immunomodulatory processes. More specifically, cytokines
may play a role in enhancing sIgA production by neonatal
leucocytes (e.g., TNFα, TGFβ2, IL6, IL10) (26, 48); in promoting
infant gut maturity and barrier function (e.g., EGF, IGF1,
TGFβ2) (23, 28, 40, 49); in boosting resistance to pathogen
colonization (38); and in dampening inflammatory responses
(e.g., IL2, IL10, TGFβ2) (6, 29, 48, 49). However, the exact
mechanisms underlying growth patterns remain speculative.
One hypothesis, proposed in the context of human milk
oligosaccharides (HMOs), is that milk composition may shift
toward a more protective profile, associated with a lower risk of
infection and inflammation, thereby enabling the infant to invest
energy in growth (7, 9, 10).
A cross-sectional preliminary study by Fields et al. suggested
that BM concentrations of cytokines (IL6, TNF-α) and
hormones/growth factors (insulin, glucose and leptin) may
differentially influence weight gain and the development of fat
and lean body mass in infants in the early postpartum period.
WHO indicators of infant growth (Z scores), however, were
not calculated or applied in their analysis (47). By contrast,
our study focussed on an important WHO indicator of growth,
WAZ, in the context of growth faltering; in our Gambian cohort,
there was a decline in WAZ in over two-thirds of infants with
15% becoming underweight by 2–3 months postpartum, despite
no infant being underweight at birth. Moreover, there was no
significant correlation between colostrum cytokine levels and
change in WAZ across the first 2–3 months post-partum, both
in the adjusted and unadjusted models. The interrelationship of
other colostrum factors, such asmicronutrients or other bioactive
analytes, including HMOs and hormones (adiponectin, insulin,
ghrelin and leptin), may play a bigger role in variable growth
outcomes and is currently under investigation (9–11, 13, 41–47,
50).
On the other hand, our findings suggest that cytokines in
mature BM may predict infant growth measured at that same
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TABLE 4 | Relationship between breast milk cytokine concentration and WAZ at final visit.
Unadjusted analysis Adjusted analysis*
Breast milk cytokine β 95% CI R2 p-value β 95% CI R2 p-value
ILIβ <−0.01 −0.003 to −0.001 0.10 <0.01 <−0.01 −0.001 to 0.001 0.02 0.81
IL2 −0.01 −0.167 to −0.028 0.09 <0.01 −0.02 −0.076 to 0.070 0.02 0.94
IL4 −0.48 −0.969 to 0.007 0.04 0.05 0.095 −0.401 to 0.592 0.02 0.70
IL6 <−0.01 −0.002 to 0.0003 0.09 <0.01 <−0.01 −0.002 to 0.000 0.17 <0.01
IL-10 −0.02 −0.058 to 0.013 0.02 0.21 0.01 −0.026 to 0.043 0.02 0.61
IL-12 −0.06 −0.188 to 0.065 0.01 0.34 0.02 −0.103 to 0.151 0.02 0.70
IL-13 −0.02 −0.066 to 0.019 0.01 0.28 0.02 −0.026 to 0.060 0.02 0.43
IFN-γ −0.02 −0.025 to −0.005 0.09 <0.01 <−0.01 −0.011 to 0.010 0.02 0.90
TNFα <−0.01 −0.004 to −0.001 0.09 <0.01 <−0.01 −0.004 to-0.001 0.17 <0.01
Unadjusted and adjusted linear regression β coefficients for breast milk cytokines predicting WAZ at final visit (*adjusted for maternal anemia).
CI, Confidence interval; WAZ, Weight-for-age Z score; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; IGF, insulin-like growth factor.
point in time. Higher levels of specific pro-inflammatory BM
cytokines were negatively associated with WAZ at the final visit
in our cohort, although the relationship was weak and clinical
significance remains as yet unclear. The relationship between
a pro-inflammatory environment and poor weight gain, both
in the fetus and infant, has been previously described (46, 51–
54). More specifically, the importance of TNFα and IL6 to early
infant growth has already been suggested by Fields et al. (47).
Higher concentrations of BM IL-6 were significantly associated
with lower relative weight, weight gain, percent fat, and fat
mass in healthy term infants at 1 month of age; higher TNF-α
significantly correlated with lower lean mass but not measures
of adiposity (47). A subsequent longitudinal study by the same
group, however, could not replicate these findings, demonstrating
only non-significant associations with infant body composition
(46).
Cytokines in mature BM may impact infant growth
through immunomodulation, as discussed earlier. Equally, these
associations may represent context-specific correlations, rather
than causation. For example, the cytokine profile in BM may
reflect maternal health at this specific time point, including
nutritional and disease status, which in turn may play a key role
in growth outcomes. Further elucidation of factors that shape
mature BM cytokine profile and understanding of underlying
mechanistic or causational processes is therefore needed. This
may have translational implications, such as the identification
of maternal groups with high risk of underweight infants, and
initiation of appropriate interventions subsequently.
Our study has several limitations. Firstly, it is a pilot
exploration of outcomes in a small maternal-infant cohort within
a limited time period. Given that (a) growth faltering is thought
to start in the first few months of life, reaching its peak by 2 years
of age in poorly-resourced settings and (b) cytokine profiles vary
within and between mothers, it would be worth analyzing BM
composition and growth outcomes in a larger cohort, at multiple
time points and beyond 3months postpartum. This would enable
a more accurate WAZ trajectory to be plotted and the longer-
term impact of BM cytokine differences to be fully appreciated.
Of note, infants are thought to demonstrate a non-linear weight
gain over this early post-partum period, and so weight at the
final time point could either reflect a change in recent infant
mass/weight or infant size more globally. Moreover, analysis of
different types of BM and at various time points not evaluated in
our study (e.g., foremilk vs. hindmilk; timing of sample collection
in relation to feeding, lactational stage, or seasonal changes) may
be valuable and has previously been shown to be important
(4, 12, 15, 16, 55).
Furthermore, our focus was on one primary growth outcome:
weight and associated WAZ scores. The latter is a well-
established WHO growth indicator, especially at birth (when
length measures may be difficult) and throughout the early
postnatal period. Weight-for-length (WLZ) and length-for-age
(LAZ) Z scores are equally important beyond the first year of life;
stunting in early childhood has been shown to predict future risk
of morbidity and mortality (32, 56) although is unlikely in the
first 90 days post-partum. Similarly, head-circumference-for-age
Z score (HAZ) is thought to be a good indicator of more chronic
poor growth and undernutrition (57–59). Other potential growth
outcomes to be measured include body composition factors (e.g.,
lean and fat mass, skinfold thickness), currently being explored
particularly in BM hormone and obesity studies (11, 13, 41, 60).
In addition, our study eligibility criteria were strict, for
example, infants born very prematurely or in poor condition
requiring resuscitation (with subsequent transfer to neonatal
intensive care) or women with high risk conditions in pregnancy
were excluded. Future studies focussing on these high-risk
groups may provide further insight into variables that regulate
BM profile and, subsequently, boost or protect against growth
faltering.
Finally, our study did not measure the contribution to early
postpartum growth of other sources of immune factors, including
the ante-and perinatal environment (cord blood, maternal non-
milk derived cytokines) and endogenous postnatal production
(infant serum). In parallel, the interplay of other bioactive factors,
such as hormones and human milk oligosaccharides, must be
explored.
In conclusion, our findings suggest that the interactions of
cytokines in both colostrum and BMdo not play a substantial role
in the early growth faltering observed in Gambian infants. Above
all, this preliminary study is valuable as a strong foundation
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to direct further investigation into the impact of bioactive
factors in BM on infant growth and development, a topic
with limited studies to date. Improved understanding of the
early postnatal determinants of growth may be important for
developing successful interventions to boost growth and health
outcomes, particularly in infants at highest risk or in poorly
resourced settings.
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